Eve Health Group Limited has released a press release.
Extension of Omniblend Innovation Tranche 2 Settlement
Filed with ASX ·
6ix hasn’t read this filing yet.
EVE Health Group Limited on 6ix
Earlier from EVE Health
- Non-Renounceable Issue
- GlucoControl Product Manufacturing Commences
- Fully Underwritten Rights Issue
- EVE Investments makes first medical technology investment
- EVE: Company Update
Later from EVE Health
- GlucoControl Pre-Meal Drink Launched
- GlucoControl Momentum
- Omniblend Innovation Enters into US Representation Deal
- New Study- GlucoControl Improves Long-Term Glycaemic Control
- Placement to Chinese Pharmaceutical and Investment Group
Follow EVE Health into a list and get an email when it puts out news.
Follow EVE Health